Syntex are developing a newly invented material for creating artificial heart valves. The carbon-polymer composite mimics the complex properties of native valves – thereby allowing surgeons to give patients synthetic heart valves that free them to live lives indistinguishable from having a healthy heart.

Heart valves show an incredibly complex mechanical behaviour to withstand the intense loading conditions they are subjected to by blood flowing through the heart and the vascular system. Nature has evolved an intricate hierarchical architecture of the native tissues especially suited to maintain valve function in such harsh environments for many decades.

It is extremely difficult to emulate the characteristics of native valves with synthetic tissues, which is why mechanical valves have always been a poor substitute. Patients must take blood-thinning medication for the rest of their lives to prevent clots forming on or around the valve. Meanwhile, biological valves from an animal degrade over 10-20 years – so younger patients need repeated surgery.

Dr Roberto Volpe, Senior Lecturer in Chemical Engineering at Queen Mary University of London, has invented a new material for creating synthetic tissues. The material is created by bonding tiny pyrolytic carbon particles into a polymer to create composite membranes which can be fine-tuned for rigidity and flexibility – anisotropic properties which mimic natural tissue and are hard to replicate using polymers alone.

Syntex have secured investment to fund ongoing testing and development of the new material – putting them on track to become a leader in R&D of synthetic tissue for biomedical applications.

5,000 heart valve replacement surgeries take place in Britain each year, and over 100,000 in the United States. Europe is leading the global aortic valve replacement market with a market value of $3.5bn billion in 2021 which is expected to grow to $9.1bn by 2030. The global aortic valve replacement market size was valued at $10.7bn in 2021 and is expected to reach $33.5bn by 2030.

The technology could also be used in the wider cardiovascular system and in neurosurgery. Syntex will work with large polymer manufacturers to fine-tune their materials to specific applications rather than building new polymers from scratch.